Related Experiment Videos
Gonadal changes in nephrological patients treated with cyclophosphamide.
Boletin Medico Del Hospital Infantil De Mexico
|May 1, 1976
Summary
Immunosuppressive drugs for kidney disease pose risks, especially to males. Lower doses and shorter treatment durations are safer, with careful risk-benefit evaluation crucial for all patients.
Area of Science:
- Nephrology
- Endocrinology
- Oncology
Background:
- Therapeutic use of immunosuppressive drugs has risen for progressive renal diseases.
- Concerns exist regarding severe gonadal damage from such treatments.
- Careful case evaluation is needed before initiating immunosuppressive therapy.
Purpose of the Study:
- To investigate gonadal lesions in patients treated with cyclophosphamide or chlorambucil.
- To assess the long-term effects of immunosuppressive therapy on gonadal function.
- To determine risk factors and safe parameters for immunosuppressive drug use in renal disease.
Main Methods:
- Studied 19 patients (9 females, 10 males) treated with cyclophosphamide or chlorambucil for progressive renal diseases.
- Evaluated females using vaginal smears, gonadotropins, and 17-ketosteroids.
- Assessed males through evaluation of gonadal function, testicular biopsy, and sperm analysis (azoospermia).
Main Results:
- No gonadal alterations were found in females; two achieved successful pregnancies.
- Males showed higher risks, with 7 exhibiting azoospermia and 4 developing testicular atrophy.
- The patient receiving chlorambucil was among those with severe gonadal damage.
Conclusions:
- Immunosuppressive therapy carries a lower risk for females than for males.
- A thorough risk-benefit analysis is imperative before initiating immunosuppressive treatment.
- Doses under 2 mg/kg/day for durations not exceeding 6 weeks appear safer.